pillbase.ru

Yorvipath

Active substance: palopegteriparatide

palopegteriparatide

Centralised EU authorisationActive

Marketing holder: Ascendis Pharma Bone Diseases A/S

Verified 2026-10-09 · EMA

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
US 3
  • Yorvipath
    INJECTION, SOLUTION · PALOPEGTERIPARATIDE 420 ug/1.4mL
    73362-102
    Ascendis Pharma, Endocrinology, Inc.
  • Yorvipath
    INJECTION, SOLUTION · PALOPEGTERIPARATIDE 168 ug/.56mL
    73362-100
    Ascendis Pharma, Endocrinology, Inc.
  • Yorvipath
    INJECTION, SOLUTION · PALOPEGTERIPARATIDE 294 ug/.98mL
    73362-101
    Ascendis Pharma, Endocrinology, Inc.
Import and control

Control by country

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208c-2ecc-731b-9480-4e5dd6b97971,01a12090-f064-7828-afb4-a7c4c406309f,01a12095-1cf6-7cbc-98c4-4cd5bdebf704;count=3 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
EMEA/H/C/005934
Registration status
Active
ATC code
H05AA
Sources
  • product · EMA · EMEA/H/C/005934 · Verified 2026-10-09
  • registration_status · EMA · EMEA/H/C/005934 · Verified 2026-10-09
  • ingredients.0 · EMA · EMEA/H/C/005934 · Verified 2026-10-09